Here is the design of a clinical trial:

Official Title: Re-engineering Precision Therapeutics Through N-of-1 Trials: Feasibility Study of Personalized Trials of Light Therapy for Fatigue

Included conditions:
- Fatigue

Study Armgroups:
- {'label': 'Bright Light Therapy', 'type': 'EXPERIMENTAL', 'description': 'Individuals will receive bright blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Bright blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total). Bright blue light treatment has been previously identified as an efficacious treatment for fatigue. It has also been shown in a number of studies that the blue wavelength of light is a key component to the shift of fatigue measures in patient reported outcomes.', 'interventionNames': ['Device: Bright Blue Light Commercial AYO Light Therapy Device']}
- {'label': 'Dim Light Therapy', 'type': 'ACTIVE_COMPARATOR', 'description': 'Individuals will receive dim blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Dim blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total).', 'interventionNames': ['Device: Dim Blue Light Commercial AYO Light Therapy Device']}
- {'label': 'Usual Care', 'type': 'NO_INTERVENTION', 'description': 'During usual care periods, participants will be instructed to abstain from use of AYO light therapy devices, and instructed to treat their fatigue as they normally would. Usual care will be presented in 2 periods each 2 weeks in length (4 weeks total).'}

Interventions:
- {'type': 'DEVICE', 'name': 'Bright Blue Light Commercial AYO Light Therapy Device', 'description': 'AYO light therapy glasses are a commercially available device which have 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and typical irradiance (100% intensity) of approximately 250 µW/cm². AYO bright light glasses are classified as "exempt" for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471).', 'armGroupLabels': ['Bright Light Therapy']}
- {'type': 'DEVICE', 'name': 'Dim Blue Light Commercial AYO Light Therapy Device', 'description': 'AYO light therapy glasses were made available to the research team by the vendor. The device has 4 Light-emitting diodes (LEDs) with a dominant wavelength of approximately 470nm ± 2nm and reduced irradiance (1% intensity) of approximately 250 µW/cm². AYO dim light glasses are classified as "exempt" for photo-biological risk based on the international standard and conformity assessment for photo-biological safety of lamps (IEC 62471).', 'armGroupLabels': ['Dim Light Therapy']}

Primary Outcomes:
- {'measure': 'Mean System Usability Score (SUS).', 'description': 'The SUS is a validated 10-item questionnaire that asks users to score each item on a Likert scale from Strongly Disagree (rating of 1) to Strongly Agree (rating of 5). The SUS will be presented to the participant as addressing the ease of use, complexity, consistency of the Personalized Trials system as a whole, from recruitment to receipt of the report. Individual results are calculated to arrive at a composite measure out of 100. Participant SUS scores will be averaged together and an overall mean will be reported with standard deviation. Higher scored values correlate to a more usable system, and therefore a better outcome.', 'timeFrame': 'Assessed once after the results report has been sent to the participant, within 4 months of intervention completion.'}

Please estimate the sample size based on the assumption: 
A 1-sample binomial test at a 2.5% significance level (1-sided) with approximately 90% power. The standard error (SE) is expected to be no greater than 8% in estimating the rate of SUS ≥85.
Sample size calculation
        The sample size of 60 participants was chosen to ensure a sufficient number of participants to obtain a preliminary assessment of the feasibility of this series of N-of-1 trials of BL and DL therapy for fatigue. In the current study, feasibility is determined by participant scores on the SUS. The numbers of assessment measures and treatment repetitions per trial were based on expert recommendations by a statistician and their estimations about the maximal duration of the trial to maintain patient engagement. The primary endpoint is trial completion in the first 3 months. We aim to demonstrate a trial completion rate greater than 50% in randomised participants. With n=60âand use of a 1-sample binomial test at 2.5% significance 1-sided, we will have approximately 90% power if the true completion rate is 70%. With 60 randomised participants, expecting a trial completion rate of 70%, we anticipate SUS data are available in about 42 participants, thus giving an SE no greater than 8% in estimating the rate of SUS â¥85, an exceptional level of usability.46 The SE will be the largest when the trial completion rate is at 50%. Data will be reported transparently so that individual-level heterogeneity can be assessed.47